Synthetic biology and microbioreactor platforms for programmable production of biologics at the point-of-care

Nature Communications

Volumn 7, Issue , 2016, Pages

  Perez Pinera, Pablo ^a,b,e   Han, Ningren ^b   Cleto, Sara ^a,b   Cao, Jicong ^a,b   Purcell, Oliver ^a,b   Shah, Kartik A ^b   Lee, Kevin ^c   Ram, Rajeev ^b   Lu, Timothy K ^a,b,d  

^a Massachusetts Institute of Technology   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c Pharyx Inc   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e University of Illinois at Urbana Champaign   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; HUMAN GROWTH HORMONE; BIOLOGICAL PRODUCT; ESTRADIOL; RECOMBINANT PROTEIN;

BIOLOGY; BIOREACTOR; BIOTECHNOLOGY; CELLS AND CELL COMPONENTS; DISEASE TREATMENT; GENETIC ENGINEERING; INFRASTRUCTURE; MANUFACTURING; PHARMACEUTICAL INDUSTRY; YEAST;

ANIMAL CELL; ARTICLE; BIOLOGICAL THERAPY; BIOREACTOR; CHO CELL LINE; CONTROLLED STUDY; FUNGAL STRAIN; GENETIC ENGINEERING; KOMAGATAELLA PASTORIS; MICROBIOREACTOR; MICROFLUIDICS; NONHUMAN; POINT OF CARE TESTING; PROTEIN SECRETION; SYNTHETIC BIOLOGY; BIOSYNTHESIS; EVALUATION STUDY; GENETIC TRANSFORMATION; METABOLISM; PICHIA; POINT OF CARE SYSTEM;

PICHIA PASTORIS;

BIOLOGICAL PRODUCTS; BIOREACTORS; ESTRADIOL; GENETIC ENGINEERING; PICHIA; POINT-OF-CARE SYSTEMS; RECOMBINANT PROTEINS; SYNTHETIC BIOLOGY; TRANSFORMATION, GENETIC;

EID: 84982702468     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12211     Document Type: Article

References (41)

1. Thiel, K. A. Biomanufacturing, from bust to boom...to bubble? Nat. Biotechnol. 22, 1365-1372 (2004).
2. Dove, A. Uncorking the biomanufacturing bottleneck. Nat. Biotechnol. 20, 777-779 (2002).
3. Gottschalk, U., Brorson, K. & Shukla, A. A. The need for innovation in biomanufacturing. Nat. Biotechnol. 30, 489-492 (2012).
4. Farid, S. S., Thompson, B. & Davidson, A. in 10th Annual bioProcess UK Conference, MAbs 6, 1357-1361 (3-4, December 2013, London, UK, 2014).
5. Hwang, T. J. Stock market returns and clinical trial results of investigational compounds: an event study analysis of large biopharmaceutical companies. PLoS ONE 8, e71966 (2013).
6. Ledford, H. First biosimilar drug set to enter US market. Nature 517, 253-254 (2015).
7. Siganporia, C. C., Ghosh, S., Daszkowski, T., Papageorgiou, L. G. & Farid, S. S. Capacity planning for batch and perfusion bioprocesses across multiple biopharmaceutical facilities. Biotechnol. Prog. 30, 594-606 (2014).
8. Willke, R. J. et al. Melding regulatory, pharmaceutical industry, and U.S. payer perspectives on improving approaches to heterogeneity of treatment effect in research and practice. Value Health 16, S10-S15 (2013).
9. Zhu, J. Mammalian cell protein expression for biopharmaceutical production. Biotechnol. Adv. 30, 1158-1170 (2012).
10. Goldrick, S., Stefan, A., Lovett, D., Montague, G. & Lennox, B. The development of an industrial-scale fed-batch fermentation simulation. J. Biotechnol. 193, 70-82 (2015).
11. Diel, B., Manzke, C. & Peuker, T. Flexible biomanufacturing processes that address the needs of the future. Adv. Biochem. Eng. Biotechnol. 138, 207-237 (2014).
12. Berlec, A. & Strukelj, B. Current state and recent advances in biopharmaceutical production in Escherichia coli, yeasts and mammalian cells. J. Ind. Microbiol. Biotechnol. 40, 257-274 (2013).
13. Mattanovich, D. et al. Recombinant protein production in yeasts. Methods Mol. Biol. 824, 329-358 (2012).
14. Vervecken, W. et al. In vivo synthesis of mammalian-like, hybrid-type N-glycans in Pichia pastoris. Appl. Environ. Microbiol. 70, 2639-2646 (2004).
15. Vervecken, W., Callewaert, N., Kaigorodov, V., Geysens, S. & Contreras, R. Modification of the N-glycosylation pathway to produce homogeneous, human-like glycans using GlycoSwitch plasmids. Methods Mol. Biol. 389, 119-138 (2007).
16. Zhang, N. et al. Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study. MAbs 3, 289-298 (2011).
17. Macauley-Patrick, S., Fazenda, M. L., McNeil, B. & Harvey, L. M. Heterologous protein production using the Pichia pastoris expression system. Yeast 22, 249-270 (2005).
18. Vogl, T., Hartner, F. S. & Glieder, A. New opportunities by synthetic biology for biopharmaceutical production in Pichia pastoris. Curr. Opin. Biotechnol. 24, 1094-1101 (2013).
19. Prielhofer, R. et al. Induction without methanol: novel regulated promoters enable high-level expression in Pichia pastoris. Microb. Cell Fact. 12, 5 (2013).
20. Koller, A., Valesco, J. & Subramani, S. The CUP1 promoter of Saccharomyces cerevisiae is inducible by copper in Pichia pastoris. Yeast 16, 651-656 (2000).
21. Resina, D., Cos, O., Ferrer, P. & Valero, F. Developing high cell density fed-batch cultivation strategies for heterologous protein production in Pichia pastoris using the nitrogen source-regulated FLD1 promoter. Biotechnol. Bioeng. 91, 760-767 (2005).
22. Cereghino, J. L. & Cregg, J. M. Heterologous protein expression in the methylotrophic yeast Pichia pastoris. FEMS Microbiol. Rev. 24, 45-66 (2000).
23. Yamaguchi, S. et al. A method for producing transgenic cells using a multi-integrase system on a human artificial chromosome vector. PLoS ONE 6, e17267 (2011).
24. Khalil, A. S. et al. A synthetic biology framework for programming eukaryotic transcription functions. Cell 150, 647-658 (2012).
25. McIsaac, R. S. et al. Synthetic gene expression perturbation systems with rapid, tunable, single-gene specificity in yeast. Nucleic Acids Res. 41, e57 (2013).
26. Perez-Pinera, P. et al. Synergistic and tunable human gene activation by combinations of synthetic transcription factors. Nat. Methods 10, 239-242 (2013).
27. Polstein, L. R. & Gersbach, C. A. Light-inducible spatiotemporal control of gene activation by customizable zinc finger transcription factors. J. Am. Chem. Soc. 134, 16480-16483 (2012).
28. Day, C. D. et al. Transgene integration into the same chromosome location can produce alleles that express at a predictable level, or alleles that are differentially silenced. Genes Dev. 14, 2869-2880 (2000).
29. Ramirez, A. et al. Sequence and chromosomal context effects on variegated expression of keratin 5/lacZ constructs in stratified epithelia of transgenic mice. Genetics 158, 341-350 (2001).
30. Chen, M. T. et al. Generation of diploid Pichia pastoris strains by mating and their application for recombinant protein production. Microb. Cell Fact. 11, 91 (2012).
31. Degelmann, A. et al. Strain and process development for the production of human cytokines in Hansenula polymorpha. FEMS Yeast Res. 2, 349-361 (2002).
32. Law, V. et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 42, D1091-D1097 (2014).
33. Lee, K. S., Boccazzi, P., Sinskey, A. J. & Ram, R. J. Microfluidic chemostat and turbidostat with flow rate, oxygen, and temperature control for dynamic continuous culture. Lab Chip 11, 1730-1739 (2011).
34. Clincke, M. F. et al. Very high density of CHO cells in perfusion by ATF or TFF in WAVE bioreactor. Part I. Effect of the cell density on the process. Biotechnol. Prog. 29, 754-767 (2013).
35. Drugs.com. http://www.drugs.com/dosage/nutropin-aq.html (2015).
36. Bareither, R. & Pollard, D. A review of advanced small-scale parallel bioreactor technology for accelerated process development: current state and future need. Biotechnol. Prog. 27, 2-14 (2011).
37. Siuti, P., Yazbek, J. & Lu, T. K. Synthetic circuits integrating logic and memory in living cells. Nat. Biotechnol. 31, 448-452 (2013).
38. Yang, L. et al. Permanent genetic memory with41-byte capacity. Nat. Methods 11, 1261-1266 (2014).
39. Warikoo, V. et al. Integrated continuous production of recombinant therapeutic proteins. Biotechnol. Bioeng. 109, 3018-3029 (2012).
40. Lee, K. S. & Ram, R. J. Plastic-PDMS bonding for high pressure hydrolytically stable active microfluidics. Lab Chip 9, 1618-1624 (2009).
41. Mozdzierz, N. J. et al. A perfusion-capable microfluidic bioreactor for assessing microbial heterologous protein production. Lab Chip 15, 2918-2922 (2015).